---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-247640"
form_type: "8-K"
ticker: "MDXG"
cik: "0001376339"
company_name: "MIMEDX GROUP, INC."
filed_at: "2024-10-30T23:59:59+00:00"
generated_at: "2026-05-30T08:08:14.954440+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MiMedx Q3 net sales $84M (+3% YoY); raises FY2024 growth outlook to high single-digits

## Summary
- GAAP net income $8.1M ($0.05 EPS); Adjusted EBITDA $18.2M (21.6% margin), up from $17.6M a year ago.
- Cash and cash equivalents $89M; net cash position $70M, up $20M sequentially.
- 2024 net sales growth guidance raised to high single-digits (from mid-to-high single-digits); Adjusted EBITDA margin expected above 20%.
- Q3 gross margin 81.8% vs 81.9% prior year; growth driven by AMNIOEFFECT, EPIEFFECT and HELIOGEN products.

## SEC filing metadata
- accession: 0001193125-24-247640
- form_type: 8-K
- ticker: MDXG
- cik: 0001376339
- company_name: MIMEDX GROUP, INC.
- filed_at: 2024-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1376339/000119312524247640/0001193125-24-247640-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1376339/000119312524247640/d117946d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-247640
- JSON: https://secwatch.observer/filing/0001193125-24-247640.json
- Plain text: https://secwatch.observer/filing/0001193125-24-247640.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.